News
The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback